This study will assess if administration of Niagen (nicotinamide riboside, or NR) can reduce viral burden and inflammation in mouse and hamster models of COVID-19.
ChromaDex's patent-protected NR is a unique nutrient that supports cellular energy production and healthy mitochondrial function through efficient restoration of NAD+ levels.
The study is part of the ChromaDex External Research Program in which ChromaDex's NR ingredient and placebos are provided to researchers at no cost.
This joint study is designed to assess in mice and hamsters whether NR supplementation prior to infection can reduce progression of the infection either by limiting viral replication or modulating the inflammatory response, having a positive impact on disease severity and duration, as well as increasing survival.
A recent preclinical study showed SARS-CoV-2 infected cells suffer significant NAD+ depletion leading to disruption of innate anti-viral immune activity, while other preclinical data suggest that modulation of inflammasome activity in immune cells by NAD+ may be important in the severe inflammation observed in patients infected with COVID-19.
ChromaDex's Niagen is proven to effectively restore and maintain NAD+ levels.
The study will be conducted at the Rocky Mountain Labs of the NIH-NIAID.
This preclinical work builds on current trans-NIAID efforts to better understand SARS–CoV-2 pathogenesis, transmission, and mechanisms of protective immunity by expanding resources and activities that support rapid development of biomedical tools to more effectively combat this disease and pandemic.
ChromaDex scientists partner with universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health.
Its flagship ingredient, Niagen nicotinamide riboside, sold directly to consumers as Tru Niagen, is backed with clinical and scientific research, as well as extensive IP protection.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary